Search Results - "Garcia Manero, Guillermo"

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management by Garcia‐Manero, Guillermo

“…Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and…”
Get full text

Myelodysplastic syndromes: 2014 update on diagnosis, risk‐stratification, and management by Garcia‐Manero, Guillermo

“…Disease overview: The myelodysplastic (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk…”
Get full text

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management by Garcia‐Manero, Guillermo, Chien, Kelly S., Montalban‐Bravo, Guillermo

“…Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and…”
Get full text

Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management by Montalban‐Bravo, Guillermo, Garcia‐Manero, Guillermo

“…Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and…”
Get full text

Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management by Garcia‐Manero, Guillermo

“…Disease overview: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and…”
Get full text

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia by Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina, Ning, Jing, Xiao, Lianchun, Hidalgo Lopez, Juliana, Kornblau, Steve M., Andreeff, Michael, Flores, Wilmer, Bueso‐Ramos, Carlos, Blando, Jorge, Galera, Pallavi, Calvo, Katherine R., Al‐Atrash, Gheath, Allison, James P., Kantarjian, Hagop M., Sharma, Padmanee, Daver, Naval G.

“…Background Phenotypic characterization of immune cells in the bone marrow (BM) of patients with acute myeloid leukemia (AML) is lacking. Methods T‐cell…”
Get full text

Time to blur the blast boundaries by DiNardo, Courtney D., Garcia‐Manero, Guillermo, Kantarjian, Hagop M.

“…A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for…”
Get full text

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML by DiNardo, Courtney D., Ravandi, Farhad, Agresta, Sam, Konopleva, Marina, Takahashi, Koichi, Kadia, Tapan, Routbort, Mark, Patel, Keyur P., Mark Brandt, Pierce, Sherry, Garcia‐Manero, Guillermo, Cortes, Jorge, Kantarjian, Hagop

“…The pathophysiology of IDH mutations in tumorigenesis is increasingly described, yet the prognostic significance of IDH1 and IDH2 mutations in AML remains…”
Get full text

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage by Jabbour, Elias, Sasaki, Koji, Ravandi, Farhad, Huang, Xuelin, Short, Nicholas J., Khouri, Maria, Kebriaei, Partow, Burger, Jan, Khoury, Joseph, Jorgensen, Jeffrey, Jain, Nitin, Konopleva, Marina, Garcia‐Manero, Guillermo, Kadia, Tapan, Cortes, Jorge, Jacob, Jovitta, Montalbano, Kathryn, Garris, Rebecca, O’Brien, Susan, Kantarjian, Hagop M.

“…Background The outcomes of patients with relapsed or refractory (R‐R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have…”
Get full text

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia by Sasaki, Koji, Kanagal‐Shamanna, Rashmi, Montalban‐Bravo, Guillermo, Assi, Rita, Jabbour, Elias, Ravandi, Farhad, Kadia, Tapan, Pierce, Sherry, Takahashi, Koichi, Nogueras Gonzalez, Graciela, Patel, Keyur, Soltysiak, Kelly A., Cortes, Jorge, Kantarjian, Hagop M., Garcia‐Manero, Guillermo

“…Background The impact of the allelic burden of ASXL1, DNMT3A, JAK2, TET2, and TP53 mutations on survival remains unclear in patients with newly diagnosed acute…”
Get full text

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes by Kadia, Tapan M., Jain, Preetesh, Ravandi, Farhad, Garcia‐Manero, Guillermo, Andreef, Michael, Takahashi, Koichi, Borthakur, Gautam, Jabbour, Elias, Konopleva, Marina, Daver, Naval G., Dinardo, Courtney, Pierce, Sherry, Kanagal‐Shamanna, Rashmi, Patel, Keyur, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop M.

“…BACKGROUND Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML). METHODS Peripheral blood or…”
Get full text

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis by Jabbour, Elias J., Sasaki, Koji, Ravandi, Farhad, Short, Nicholas J., Garcia‐Manero, Guillermo, Daver, Naval, Kadia, Tapan, Konopleva, Marina, Jain, Nitin, Cortes, Jorge, Issa, Ghayas C., Jacob, Jovitta, Kwari, Monica, Thompson, Philip, Garris, Rebecca, Pemmaraju, Naveen, Yilmaz, Musa, O’Brien, Susan M., Kantarjian, Hagop M.

“…Background The outcome of older patients with newly diagnosed, Philadelphia chromosome (Ph)‐negative acute lymphoblastic leukemia (ALL) is poor. The…”
Get full text

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors by Haddad, Fadi G., Sasaki, Koji, Issa, Ghayas C., Garcia‐Manero, Guillermo, Ravandi, Farhad, Kadia, Tapan, Cortes, Jorge, Konopleva, Marina, Pemmaraju, Naveen, Alvarado, Yesid, Yilmaz, Musa, Borthakur, Gautam, DiNardo, Courtney, Jain, Nitin, Daver, Naval, Short, Nicholas J., Jabbour, Elias, Kantarjian, Hagop

“…Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia‐chromosome‐positive chronic myeloid leukemia (Ph‐positive CML) is increasingly…”
Get full text

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study by Takahashi, Koichi, MD, Wang, Feng, PhD, Kantarjian, Hagop, Prof, Doss, Denaha, MS, Khanna, Kanhav, MS, Thompson, Erika, MS, Zhao, Li, PhD, Patel, Keyur, MD, Neelapu, Sattva, MD, Gumbs, Curtis, BS, Bueso-Ramos, Carlos, Prof, DiNardo, Courtney D, MD, Colla, Simona, PhD, Ravandi, Farhad, Prof, Zhang, Jianhua, PhD, Huang, Xuelin, PhD, Wu, Xifeng, Prof, Samaniego, Felipe, MD, Garcia-Manero, Guillermo, Prof, Futreal, P Andrew, Prof

“…Summary Background Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence…”
Get full text

Dr. Elihu H. Estey (1946–2021) by Garcia‐Manero, Guillermo, Pierce, Sherry, Ravandi, Farhad, Kantarjian, Hagop

Get full text

Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia by Ohanian, Maro, Garcia‐Manero, Guillermo, Levis, Mark, Jabbour, Elias, Daver, Naval, Borthakur, Gautam, Kadia, Tapan, Pierce, Sherry, Burger, Jan, Richie, Mary Ann, Patel, Keyur, Andreeff, Michael, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop, Ravandi, Farhad

“…Based on our previous study of the combination of sorafenib with 5‐azacytidine (AZA) in relapsed/refractory patients with FLT3 mutated acute myeloid leukemia…”
Get full text

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results by Kantarjian, Hagop, Short, Nicholas J., Jain, Nitin, Sasaki, Koji, Huang, Xuelin, Haddad, Fadi G., Khouri, Issa, DiNardo, Courtney D., Pemmaraju, Naveen, Wierda, William, Garcia‐Manero, Guillermo, Kebriaei, Partow, Garris, Rebecca, Loghavi, Sanam, Jorgensen, Jeffrey, Kwari, Monica, O'Brien, Susan, Ravandi, Farhad, Jabbour, Elias

“…The combination of ponatinib, a third‐generation BCR::ABL1 tyrosine kinase inhibitor, with hyper‐CVAD chemotherapy resulted in high rates of complete molecular…”
Get full text

Oncogenic functions of the transcription factor Nrf2 by Gañán-Gómez, Irene, Wei, Yue, Yang, Hui, Boyano-Adánez, María Carmen, García-Manero, Guillermo

“…Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that controls the expression of a large pool of antioxidant and cytoprotective genes…”
Get full text

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia by Saxena, Kapil, Herbrich, Shelley M., Pemmaraju, Naveen, Kadia, Tapan M., DiNardo, Courtney D., Borthakur, Gautam, Pierce, Sherry A., Jabbour, Elias, Wang, Sa A., Bueso‐Ramos, Carlos, Loghavi, Sanam, Tang, Guillin, Cheung, Cora M., Alexander, Lynette, Kornblau, Steven, Andreeff, Michael, Garcia‐Manero, Guillermo, Ravandi, Farhad, Konopleva, Marina Y., Daver, Naval

“…Background Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have limited treatment options. In preclinical models of AML, inhibition of the…”
Get full text

Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy by Venugopal, Sangeetha, Shoukier, Mahran, Konopleva, Marina, Dinardo, Courtney D., Ravandi, Farhad, Short, Nicholas J., Andreeff, Michael, Borthakur, Gautam, Daver, Naval, Pemmaraju, Naveen, Sasaki, Koji, Montalban‐Bravo, Guillermo, Marx, Kayleigh R., Pierce, Sherry, Popat, Uday R., Shpall, Elizabeth J., Kanagal‐Shamanna, Rashmi, Garcia‐Manero, Guillermo, Kantarjian, Hagop M., Kadia, Tapan M.

“…Background Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not…”
Get full text